RSC Advances



PAPER

Check for updates

Cite this: RSC Adv., 2021, 11, 23627

Absolute content determination by quantitative NMR (qNMR) spectroscopy: a curious case of aldosterone[†]

Neeraj Singh, 💿 * Judith Taibon, Stephan Pongratz and Christian Geletneky*

Received 4th May 2021 Accepted 19th June 2021 DOI: 10.1039/d1ra03472c

rsc.li/rsc-advances


Quantitative NMR spectroscopy has been utilized to calculate the absolute content (g g^{-1}) of aldosterone, which is necessary for electrolyte balance and blood pressure regulation, in commercially available materials. Explanations have been provided for many signals observed in the ¹HNMR spectrum, false interpretation of which can have significant effects if such a value is utilized for the primary calibrators in ID-LC-MS/MS ('gold standard') reference methods in clinical chemistry.

Aldosterone (Scheme 1), a mineralocorticoid hormone, plays a dominant role (renin–angiotensin system) in maintaining electrolyte balance by regulating Na⁺ and K⁺ ion levels in plasma and in homoeostatic regulation of blood pressure.¹ It is synthesized by *Zona glomuerulosa* in the adrenal cortex of suprarenal glands. Adrenal cortex disorders leading to hyper/ hypo-aldosteronism, make it an important parameter in clinical chemical diagnostics.^{1,2}

Diverse diagnostic assays are utilized for the quantification of clinically relevant analytes such as aldosterone in whole blood, but nowadays, ID-LC-MS/MS based analytics have become the method of choice owing to their higher specificity, sensitivity and accuracy. Normally, an appreciable difference is found between hyphenated-MS based analysis and other assays.³ Moreover, hyphenated-MS methods⁴ do not suffer from the disadvantage of cross-reactivity with other structurally similar endogenous molecules present in the blood. Additionally, efforts are in progress by JCTLM (Joint Committee for Traceability in Laboratory Medicine) and IFCC (International Federation of Clinical Chemistry and Laboratory Medicine) for the development of 'ID-LC-MS/MS based Reference Methods' for the standardization of all clinical diagnostic assays.⁵ One of the most important determinant of the success and trueness of such measurements is the absolute content of the primary calibrator and it's high order traceability to SI units, in order to standardize all such assays. In case of aldosterone, however, no solid-based reference standards are available from metrological institutes.5,6

We, therefore, decided to utilize only quantitative NMR (qHNMR) spectroscopy⁷ to calculate the 'absolute content' of commercially available aldosterone (non-reference standard

materials), and to identify any side/by-products, if present. qNMR is the only analytical technique wherein the structure of the organic molecule and it's absolute content (g g⁻¹) can be ascertained in a single non-destructive method. Since the intensity of a signal in ¹HNMR is directly proportional to the amount of the resonant nuclei, the content can be calculated by comparison with an internal standard. The qNMR internal standards are either traceable to NIST Benzoic Acid (350b; coulometric) and/or NIST PS1 qNMR standard, thereby, provide unparalleled traceability to SI units.⁸⁴ Because of the high accuracy, simplicity and precision of the qHNMR analytical method, this approach is gaining fast acceptance by metrological institutes^{8b} such as NIST, NMIJ, NMIA along with chemical



Scheme 1 Structures of aldosterone tautomers and some impurities.

Roche Diagnostics, Nonnenwald 2, 82377 Penzberg, Germany. E-mail: neeraj.singh. ns1@roche.com; christian.geletneky@roche.com

[†] Electronic supplementary information (ESI) available. See DOI: 10.1039/d1ra03472c

companies such as Sigma-Aldrich (Merck), Wako, *etc.*, for the characterization and quantification of reference materials.

In this work, 1 was obtained from two sources (S1 and S2), with \geq 95% chromatographic purity (HPLC/TLC; not a massfraction (g g^{-1}) value). The NMR experiments were performed in acetonitrile-d₃, obtained from Sigma-Aldrich. In order to eliminate solvent based differences, same CD₃CN was utilized for S1 and S2. Tecnazene (qNMR Internal Standard) was also bought from Sigma-Aldrich. 1D and 2D measurements were performed, at 300 K, on a JEOL 600 MHz NMR spectrometer equipped with a He-cooled Ultra-Cool cryoprobe and/or JEOL 500 MHz NMR with a N₂-cooled Super-Cool cryoprobe. Weighing was accomplished using a METTLER-TOLEDO XPR6U ultramicro balance. For quantitative NMR experiments $({}^{1}H{}^{13}C{}$ WURST sequence) ca. 1.7-4.84 mg of 1 was weighed together with tecnazene (1.64-2.58 mg) and the mixture was dissolved in ca. 0.75 mL of CD₃CN. NMR measurements were performed in 5 mm NMR tubes, and the inter-scan delay was set to 70 s.

Structurally, aldosterone 1 (Scheme 1)⁹ is represented as 11β,21-dihydroxy-3,20-diketo-4-pregnene-18-al, characterized by the presence of an aldehyde group at C-13. However, it is well known that, steroids with an -OH at C-11, and carbonyl functionalities at C-13 and C-17 tend to form hemiacetals and/or acetals/ketals. Appropriately, 1 has been shown to exist as an equilibrating tautomeric mixture of 18-acetal-20-hemiketal form 2 and 11β ,18-oxide form 3 (Scheme 1), in solution of different solvents.10 Furthermore, even XRD findings have confirmed the presence of only tautomer 3, as a monohydrate, in solid crystals.¹¹ As a result, the parent structure 1 has never been confirmed in solution or solid state, plausibly, owing to the high reactivity of the -CHO group at C-13 and the presence of acid/base traces in solvents, thereby, promoting the setup of 2 \leftrightarrow 3 equilibrium.

Acetonitrile-d₃ was found to be a suitable solvent owing to good dissolution of aldosterone **1** and tecnazene, mainly, because the lipophobic/lipophilic nature of $-CH_3$ group/CN functional group, respectively, promotes solubility of polar as

Paper

well as apolar solutes. Additionally, excellent dispersion of spinsystems can be observed in Fig. 1, probably, owing to the local diamagnetic anisotropic interaction of the CN sp-hybridized bond with aldosterone functionalities. Since acetonitrile and/ or acetonitrile–H₂O eluent mixtures are frequently the solvents/eluents of choice for RP-UHPLC separations, the choice of AcN as NMR solvent ensures similar relative concentrations of aldosterone tautomers; although, additional pH factors can alter this equilibrium. Moreover, utilization of a polar aprotic solvent inhibits labile ¹H–²H exchange; therefore, the tautomeric equilibrium of **1** would not be affected by kinetic isotope effect.

We first utilized 1 from commercial source S1 for the quantitation experiments. As can be seen,¹² there was no signal at δ_{CHO} : 8.5–10 ppm, thereby, aldehyde form of 1 can be completely ruled out. However, we could easily find intense signals from 18*R*,20*S* 2a ($\delta_{H-4} = 5.62$ ppm, s; $\delta_{H-18} = 5.32$ ppm, s; $\delta_{\text{H-21}} = 3.36 \text{ ppm, ddd, 2H; } \delta_{\text{H-11}} = 4.75 \text{ ppm, } {}^{3}J = 5.54 \text{ Hz} \text{) and}$ 18*S*,20-oxo **3a** ($\delta_{\text{H-4}} = 5.62 \text{ ppm}$, s; $\delta_{\text{H-18}} = 4.94 \text{ ppm}$, ${}^{3}J_{\text{H-OH}} =$ 5.14 Hz; $\delta_{\text{H-21}\alpha(\text{R})} = 4.29$ ppm, dd (ABX), 1H; $\delta_{\text{H-21}\beta} = 4.11$ ppm, dd (ABX), 1H; $\delta_{H-11} = 4.50$ ppm, ${}^{3}J = 6.53$ Hz, 1H) in a ratio of 0.784 : 1 (or approx. 3 : 4) (Fig. 1).13 Both of these major diastereomers exist in a tautomeric equilibrium, and account for the actual structure of aldosterone in solution.10,13 Conveniently, H-4, in both structures 2a and 3a, was found to resonate at the same chemical shift. This signal being a nicely separated singlet with S/N of > 2000 : 1, was well-suited for utilization as the quantitation signal. Therefore, triplicate experiments were performed using H-4 as the quantification resonance, and an average absolute content of 1 was obtained to be 93.80% (Table 1). However, when 2a ($\delta_{H-18} = 5.32$ ppm) and 3a ($\delta_{H-18} = 4.94$ ppm) were quantified separately, for experiment 1 (Table 1), values of 38.82% and 49.52% were obtained, respectively. This led to a difference of 5.46% in the absolute content of aldosterone 1, when a summation of the count of 2a and 3a was compared to the olefinic signal at $\delta_{H-4} = 5.62$ ppm. Therefore, on a closer look of the qHNMR spectrum, we found more




Fig. 1 Overlay of ¹H{¹³C}NMR spectra of aldosterone 1 (S1: red; S2: blue) indicating the various diastereomers 2a, 2b, 3a, 3b along with the 2D-gHSQCAD spectrum (S1 material).

Aldosterone source	Analyte weighed (mg)	ISTD weighed (mg)	qNMR absolute content (%)	Standard deviation
S1 (experiment 1)	3.9082	1.9430	93.91	
S1 (experiment 2)	4.8432	2.5879	93.56	
S1 (experiment 3)	2.5978	1.3418	93.93	
Average value $(n = 3)$			93.80	0.2044

Table 1 Determination of qNMR absolute content of aldosterone 1 from S1

signals which could, potentially, account for this significant discrepancy.

Before the interpretation of these signals was undertaken, we also analyzed the aldosterone **1** from commercial source S2. Here, also, similar major and minor signals were seen as observed in S1, with the exception of some signals that were not present in the ¹HNMR of **1** in S1. However, in S2 aldosterone **1**, the signals not belonging to **2a** and **3a** were more intense when compared to that in S1. A qHNMR experiment for **1** in S2 yielded a value of 81.85%, following the exact same procedure as mentioned for S1.¹² The absolute content of S1 aldosterone is clearly much better than S2, and the low content of S1 aldosterone makes it unsuitable to be utilized as a reference compound.

A quick look into already published literature, pointed towards the existence of some possible structures, as illustrated in Scheme 1, such as the dimer 4,14 aldosterone acetal 5,14 aldosterone-y-lactone 6.14 Additionally, a basic/acidic workup procedure for the synthesis of aldosterone 1, can lead to additional molecules such as vicinal diol 710c,14 and carboxylic acid 8¹⁴ (Scheme 1). The absence of sym-dimer 4 and asym-dimer 4 was confirmed by the absence of a singlet/dd at $\delta_{\text{H-21}}$ \thickapprox 3.7 ppm. The signal at $\delta_{H-21} = 3.72$ ppm in Fig. 1 corresponds to an OH/exchangeable proton, for 1, with no ${}^{1}J_{C-H}$ in 2D-HSQC spectrum.¹² Since no dd with ${}^{2}I = 16$ Hz can be observed around *ca*. $\delta_{H-21} = 4$ ppm, the presence of aldosterone- γ -lactone 6¹⁴ can also be ruled out. Aldosterone acetal 5 is also highly unlikely to be present since the synthesis involves reflux conditions, and has only been postulated to be present in aldosterone synthesis, but not found.14a Also, carboxylic acid 8 is not present since no broad singlet could be observed at $\delta_{\rm COOH}$ ≈ 11 ppm.¹²

Among the signals which are common to both S1 and S2 aldosterone **1**, besides that of **2a** and **3a**, signals at $\delta_{H-18} = 4.84 \text{ ppm}$, ${}^{3}J = 6.17 \text{ Hz}$; $\delta_{H-11} = 4.46 \text{ ppm}$, ${}^{3}J = 6.41 \text{ Hz}$; $\delta_{H\alpha-21} = 4.23 \text{ ppm}$, dd, ${}^{2}J = 19.10 \text{ Hz}$, ${}^{3}J_{H-OH} = 5.57 \text{ Hz}$; $\delta_{H\beta-21} = 4.15 \text{ ppm}$, dd, ${}^{3}J_{H-OH} = 4.15 \text{ Hz}$ (other signals of the dd spin system overlap with that of **3a**), 2H; $\delta_{H-17} = 3.24 \text{ ppm}$, dd, ${}^{3}J = 7.83$, 7.59 Hz; $\delta_{OH-21} = 3.18 \text{ ppm}$, can be attributed to the other diastereomer of **3a**, *i.e.*, 18*R*,20-0x0 **3b**.¹²⁻¹⁵ Signals of **3b** are present in significant amounts in S2, but are present only in traces in S1. Additionally, signals at $\delta_{H-18} = 5.23 \text{ ppm}$, s; $\delta_{H-11} = 4.80 \text{ ppm}$, d, ${}^{3}J = 5.69 \text{ Hz}$; $\delta_{H\alpha-21} = 3.49 \text{ ppm}$, dd, ${}^{2}J = 11.48 \text{ Hz}$, ${}^{3}J = 5.14 \text{ Hz}$; $\delta_{H\beta-21} = 3.41 \text{ ppm}$ (overlapping with that of **2a**) can be assigned to **2b**, the 18*R*,20*R* diastereomer.¹²⁻¹⁵ The intensity of the signals of **2b**, in both S1 and S2, is almost similar.

Moreover, in S2, signals are present at $\delta_{H-4} = 5.64$ ppm, s; δ_{H $_{18}$ = 4.88 ppm, ^{3}J = 6.41 Hz; $\delta_{H\alpha-21}$ = 4.33 ppm, dd, ^{2}J = 18.50 Hz, ${}^{3}J_{H-OH} = 4.74$ Hz; $\delta_{HB-21} =$ complete overlapping with the signals of 3a/3b. These signals are, however, absent in S1 aldosterone. The structure corresponding to these chemical shifts is difficult to ascertain, however; it must be added that similar splitting pattern of H-21 geminal protons and the associated chemical shift region, point towards a third diastereomer of 3. But, since no detailed data is available for this particular diastereomer, we would not like to speculate at this point. Also, the absence of these signals from S1 aldosterone 1, and down-shifted H-4 δ value, could also result from a stereochemical inversion at C-11 or from impurities present from synthesis, such as from 11β-nitrite of corticosterone acetate,^{9α-9c} which is a synthetic precursor for aldosterone. Additionally, a singlet at $\delta = 7.14$ ppm,¹² with similar integral area as compared to the above mentioned data, is too down-field shifted for any kind of aldosterone diastereomers. The exclusion of these signals would lead to a reduction in the absolute content of S2 aldosterone 1 by ca. 7%, which can have significant repercussions if this material is utilized as a primary calibrator in hyphenated-MS analytics. Since, primary calibrators should be of ultra-high purity grade $(g g^{-1})$ and have the highest order of traceability, aldosterone from S2 commercial source was found insuitable. However, it provided important clues when compared to S1 aldosterone, for the interpretation of additional diastereomers in the tautomeric equilibria of 1.

Furthermore, in case of aldosterone 1 from S1 commercial source, the inclusion of the quantitative value for **3b** (0.78%) and **2b** (3.22%), a total of 4.0% increase is observed when the quantitation signal (H-4) is compared to the sum of absolute values from 2a + 3a + 2b + 3b. This leads to a total value of 92.34%, when calculated for experiment 1. A difference of 1.57% can be explained on the basis of extremely low S/N ratio of the quantitation signals of **3b** (20 : 1) and **2b** (200 : 1). Therefore, in our opinion, qNMR can be utilized to quantify aldosterone, suitable to be a reference compound, and also at the same time, work as a universal detector (for organic components) to analyse the chemical nature of additional entities, if present, something which cannot be said for HPLC-UV based quantitations.

Conclusions

To summarize, we have presented a qHNMR based method for the quantitation of commercially available aldosterone, and also shown the challenges associated with identification of various diastereomers of hemiketal 2 and the hemiacetal 3. A high-order traceability has been clearly established to SI units owing to the traceability of the qNMR internal standard, which makes this method of quantitation appropriately comparable to 'mass-fraction $(g g^{-1})$ ' values given for reference materials. Also, in our opinion, LC-UV based quantitation values utilized for the generation of mass-fraction values, should be cross-checked with qNMR, whenever possible. Moreover, aldosterone should be represented as a hemiacetal/hemiketal structure to avoid confusion of it being considered a single molecule characterized by the presence of an aldehyde functional group. We would also like to add that suitable columns should be employed, to ensure the separation/quantification of all the hemiketal/ hemiacetal diastereomers of aldosterone tautomers, since diastereomers generally tend to have different physical properties (e.g., λ_{max} , η), and can interact in various ways with functional groups on the surface of a particular column.

Conflicts of interest

All the authors are employees of Roche Diagnostics, Nonnenwald 2, 82377 Penzberg, Germany. There are no conflicts to declare.

Acknowledgements

Authors would like to thank Ms Katrin Gradl and Dr Tobias Santner for reading the manuscript.

Notes and references

- 1 M. Briet and E. L. Schiffrin, Nat. Rev. Nephrol., 2010, 6, 261.
- 2 R. Horton, Metabolism, 1973, 22, 1525.
- 3 T. Nishikawa, Ma. Omura, M. Kawaguchi, A. Takatsu, F. Satoh, S. Ito, I. Kurihara, H. Itoh, T. Yanase, H. Shibata, Y. Oki, M. Naruse, K. Sakurai, H. Sasamoto and K. Kuwa, *Endocr. J.*, 2016, **63**, 1065.
- 4 (a) J. J. Pitt, *Clin. Biochem. Rev.*, 2009, **30**, 19; (b) S. Grebe and R. J. Singh, *Clin. Biochem. Rev.*, 2011, **32**, 5.

- 5 http://jctlm.org.
- 6 R. F. Greaves, C. S. Ho, K. E. Hoad, J. Joseph, B. McWhinney,
 J. P. Gill, T. Koal, C. Fouracre, H. P. Iu, B. R. Cooke,
 C. Boyder, H. T. Pham and L. M. Jolly, *Clin. Biochem. Rev.*, 2016, 37, 63.
- 7 (a) L. Griffiths and A. M. Irving, *Analyst*, 1998, **123**, 1061; (b) S. K. Bharti and R. Roy, *Trends Anal. Chem.*, 2012, **35**, 5.
- 8 (a) M. A. Nelson, J. F. Waters, B. Toman, B. E. Lang, A. Rück, K. Beitruck, M. Obkircher and K. A. Lippa, *Anal. Chem.*, 2018, 90, 10510; (b) NIST (National Institute of Standards and Technology); NMIJ (National Metrology Institute of Japan); NMIA (National Measurement Institute of Australia).
- 9 (a) D. H. R. Barton, N. K. Basu, M. J. Day, R. H. Hesse, M. M. Pechet and A. N. Starratt, J. Chem. Soc., Perkin Trans. 1, 1975, 2243; (b) D. H. R. Barton and J. M. Beaton, J. Am. Chem. Soc., 1960, 82, 2641; (c) D. H. R. Barton and J. M. Beaton, J. Am. Chem. Soc., 1961, 83, 4083; (d) W. S. Johnson, J. C. Collins, R. Pappo and M. B. Rubin, J. Am. Chem. Soc., 1958, 80, 2585.
- 10 (a) P. Genard, Org. Magn. Reson., 1971, 3, 759; (b) B. G. Carter, D. N. Kirk and P. J. Burke, J. Chem. Soc., Perkin Trans. 2, 1987, 1247; (c) S. A. latif, D. J. Morris, L. Wei, D. N. Kirk, P. J. Burke, H. C. Toms and C. H. L. Shackelton, J. Steroid Biochem., 1989, 33, 1119; (d) P. Genard, Org. Magn. Reson., 1978, 11, 478.
- 11 (a) W. L. Duax and H. Hauptman, J. Am. Chem. Soc., 1972, 94, 5467; (b) W. L. Duax, H. Hauptman, C. M. Weeks and D. A. Norton, Chem. Commun., 1971, 1055.
- 12 For details, see ESI.[†].
- 13 D. N. Kirk and M. S. Rajagopalan, *J. Chem. Soc., Perkin Trans.* 1, 1987, 1339.
- 14 (a) K. Lichtwald and M. Przybylski, Angew. Chem., Int. Ed., 1985, 24, 130; (b) D. N. Kirk and B. W. Miller, J. Steroid Biochem., 1982, 16, 269; (c) M. Harnik, Y. Kashman, M. Cojocaru, S. Lewicka and P. Vecsei, Steroids, 1989, 54, 11.
- 15 K. Yamashita, Y. Tadokoro, M. Takahashi and M. Numazawa, *Chem. Pharm. Bull.*, 2008, **56**, 873.